Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.

Blood - 10 May 2018

Bisserier Malik, Wajapeyee Narendra

Abstract excerpt

Resistance to targeted therapies has become increasingly prevalent. We noted that resistance to different targeted therapies occurs by largely common mechanisms. In this study, we used this information for identifying the mechanisms of resistance to enhancer of zeste homolog 2 (EZH2) inhibitors in diffuse large B-cell lymphoma (DLBCL) harboring EZH2 mutations. We discovered that EZH2 inhibitor-resistant DLBCL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Lymphoma, Large B-Cell, Diffuse
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, IGF Type 1

Share to Receptors, Somatomedin

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29572378
DOI: 10.1182/blood-2017-08-804344
PMCID: PMC5946763

Genes

BAD
FOXO3
TNFSF10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.PMID 29572378Read ↗

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.Semantic proximity Read ↗

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).Semantic proximity Read ↗

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.Semantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read ↗

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read ↗

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsSemantic proximity Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.